Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd PharmaphorumBoehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.RespiratoryRead full story pharminent July 9, 2026 (Last updated: July 9, 2026) Pharmaphorum Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK. Respiratory Read full story Post navigation Previous: FDA Warning Letter Hits Sanofi’s Genzyme Ireland SiteNext: NICE aims to cut funding for Amgen lung cancer drug Lumykras Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026